This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Illinois Prescription Monitoring Program | |
|---|---|
| Name | Illinois Prescription Monitoring Program |
| Other names | I-PMP |
| Formed | 2011 |
| Jurisdiction | Illinois |
| Parent agency | Illinois Department of Public Health |
Illinois Prescription Monitoring Program is a state-run electronic database designed to collect, monitor, and analyze prescription records for controlled substances dispensed within Illinois. It supports clinical decision-making for prescribers and pharmacists while assisting law enforcement, public health officials, and policymakers in addressing prescription drug misuse. The program interfaces with health information technology initiatives and regulatory frameworks to reduce diversion, addiction, and overdose.
The program aggregates dispensing data from pharmacies, pharmacists, and licensed prescribers, creating a longitudinal patient-level record similar to systems used in Florida, Kentucky, Massachusetts, New York (state), and Ohio. It integrates with electronic health record vendors such as Epic Systems Corporation, Cerner Corporation, and regional health information exchanges like the Illinois Health Information Exchange. Stakeholders include the Illinois Department of Financial and Professional Regulation, state medical boards, hospital systems like Northwestern Medicine and University of Chicago Medical Center, and professional associations including the American Medical Association and American Pharmacists Association.
Origins trace to legislative responses after high-profile overdose crises and opioid-related reports similar to events influencing laws in California, Pennsylvania, and West Virginia. Statutory authorization followed national policy shifts reflected in recommendations from the U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, and the Office of National Drug Control Policy. Implementation involved procurement, vendor selection, and pilot projects coordinated with academic partners such as University of Illinois Chicago and public health researchers affiliated with Johns Hopkins University and Harvard T.H. Chan School of Public Health.
Statutory authority is derived from Illinois statutes enacted by the Illinois General Assembly and amended through subsequent sessions influenced by litigation and regulatory guidance from the Illinois Attorney General. The program's regulatory oversight interacts with rules from the Illinois State Board of Pharmacy, licensing standards of the Illinois Medical Licensing Board, and federal statutes like the Controlled Substances Act. Privacy constraints reference interpretations of the Health Insurance Portability and Accountability Act of 1996 and coordination with the Department of Veterans Affairs for veteran-related prescriptions.
Daily operations involve automated reporting by pharmacy management systems and retail chains including Walgreens, CVS Health, and Walmart (company), as well as hospital outpatient pharmacies. Data fields include patient identifiers, prescriber NPI numbers registered with the National Provider Identifier, drug National Drug Codes used in RxNorm and First Databank standards, dosage, quantity, and dispensing date. Data warehousing, analytics, and dashboarding draw on business intelligence tools used by institutions like IBM and Google Cloud Platform partners, while interoperability follows standards from Health Level Seven International and the DirectTrust network.
Authorized users include licensed physicians, nurse practitioners, physician assistants, and pharmacists under role-based access controls consistent with guidance from Office for Civil Rights (OCR). Law enforcement access requires court orders or is limited under statutes consistent with precedents from cases in United States District Court for the Northern District of Illinois. Security practices align with frameworks published by the National Institute of Standards and Technology and employ encryption, audit trails, and multifactor authentication. Privacy advocates, academic ethicists from University of Chicago and civil liberties organizations such as the American Civil Liberties Union have engaged on safeguards and data minimization.
Evaluations by public health researchers and agencies comparable to assessments in Rhode Island and Washington (state) examine reductions in doctor-shopping, high-risk prescribing patterns, and overdose mortality trends reported by the Centers for Disease Control and Prevention. Studies by faculty at University of Illinois Urbana–Champaign and collaborating institutions have used quasi-experimental methods to measure changes in opioid prescribing, benzodiazepine co-prescribing, and transitions to illicit opioids, with comparisons to national surveillance from the National Survey on Drug Use and Health and the Substance Abuse and Mental Health Services Administration.
Critiques mirror national debates involving unintended consequences documented in literature from Columbia University Irving Medical Center and Yale School of Medicine, including potential barriers to pain management for patients with chronic conditions treated by specialists at centers like Rush University Medical Center. Concerns raised by civil liberties groups and prescriber organizations address data access, potential for profiling, interstate data sharing with programs in Indiana and Wisconsin, and adequacy of provider training. Legal challenges and policy debates have involved stakeholders such as the Illinois Trial Lawyers Association and state legislators, prompting revisions to reporting rules and user agreements.
Category:Health in Illinois Category:Prescription drug monitoring programs in the United States